Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28813910 | 0.93 | GAA (0.37) | GAATSHRKDM4EHPGDHSD17B10 | |
| SCHEMBL9894281 | 0.92 | GAA (0.33) | GAATSHRKDM4EHPGDHSD17B10 | |
| SCHEMBL1138569 | 0.88 | ESR2 (0.35) | GAATSHRKDM4EHPGDHSD17B10 | |
| SCHEMBL18411232 | 0.83 | GAA (0.43) | GAATSHRKDM4EHPGDHSD17B10 | |
| SCHEMBL28213045 | 0.77 | TSHR (0.38) | GAATSHRKDM4EESR2 | |
| SCHEMBL28043669 | 0.77 | TSHR (0.38) | GAATSHRKDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL11608 | 0.73 | TSHR (0.50) | GAATSHRL3MBTL1ALDH1A1ESR2 | |
| SCHEMBL29468918 | 0.73 | TSHR (0.50) | GAATSHRL3MBTL1ALDH1A1ESR2 | |
| 1,3-Propanediol SCHEMBL4733793 | 0.71 | TSHR (0.41) | GAATSHRKDM4EHPGDHSD17B10 | |
| SCHEMBL841740 | 0.71 | HTR1A (0.35) | GAATSHRKDM4EHPGDL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889864-B2 | Metal complexes of cyclometallated imidazo[1,2-f]phenanthridine and diimidazo[1,2-a:1′,2′-c]quinazoline ligands and isoelectronic and benzannulated analogs thereof | UNIVERSAL DISPLAY CORPORATION (US) | 2014-11-18 | — | — | US | disclosed |
| US-8142909-B2 | Blue phosphorescent imidazophenanthridine materials | UNIVERSAL DISPLAY CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | UNIVERSAL DISPLAY CORPORATION | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080297033-A1 | BLUE PHOSPHORESCENT IMIDAZOPHENANTHRIDINE MATERIALS | IK, CRY1, MAP1LC3C | GAA 3715/4885TSHR 4444/4885KDM4E 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.